Taiwan · Delayed Price · Currency is TWD PharmaEssentia Company Description
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.
Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia.
The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology.
PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 1990 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Ko-Chung Lin |
Contact Details
Address: No. 3, Park Street Taipei, 115 Taiwan | |
| Phone | 886 2 2655 7688 |
| Website | pharmaessentia.com |
Stock Details
| Ticker Symbol | 6446 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006446008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ko-Chung Lin Ph.D. | Founder, Chief Executive Officer, Chief Strategy Officer and Director |
| Chan-Kou Hwang Ph.D. | President, GM and Director |
| Snow Chang | Director of Finance |
| Samuel Lin | Vice President and Head of Business Operations and Strategy |
| Lih-Ling Lin Ph.D. | Chief Scientific Officer |
| Hsing-I Chen | General Counsel |
| Dr. Albert Qin M.D., Ph.D. | Chief Medical Officer |
| Narihisa Miyachi | Head of Japan Medical Affairs |
| Yen-Tung Luan | Chief Operating Officer of Taichung Plant |
| Wu Kuo-Hsiung | Chief of Taichung Plant |